Related Experiment Video
Updated: May 16, 2026

Intracranial Subarachnoidal Route of Infection for Investigating Roles of Streptococcus suis Biofilms in Meningitis in a Mouse Infection Model
Published on: July 1, 2018
[Recent trend in subacute meningitides]
1Division of Neurology, Department of Medicine, Nihon University School of Medicine.
Abstract:
Recent clinical management of subacute meningitis is reviewed. Tuberculous meningitis (TbM) and fungal meningitis are the commonest cause of subacute meningitis. Since the delayed treatment in these meningitides is strongly associated with poor outcome, these clinical managements are required to be neurological emergency. Recent clinical guidelines of these meningitides recommended new therapeutic managements. Treatment for TbM should consist of 4 drugs (isoniazid, rifampicin, pyrazinamide, ethambutol) for 2 months followed by 2 drugs (isoniazid, rifampicin) for at least 10 months. Adjunctive corticosteroids should be given to all non-HIV patients with TbM, regardless of disease severity. Treatment for CNS Cryptococcosis and Candidiasis with non-HIV infected and non-transplant hosts is lipid formulation of Amphotericin B combined with flucytosine for at least 4 weeks for induction therapy. This 4-week induction therapy is reserved for patients with meningoencephalitis without neurological complications and CSF yeast culture results that are negative after 2 weeks of treatment. Then, the consolidation with fluconazole for 8 weeks is started. Voriconazole is recommended for the primary treatment of CNS Aspergillosis including meningitis. If the diagnosis is made early, if clinicians adhere to the basic principles of these guidelines, and if the underlying disease is controlled, these meningitides could be managed successfully in the most of patients.
Insights
Subacute meningitis, particularly tuberculous (TbM) and fungal types, requires urgent neurological management. Adhering to updated guidelines with specific drug regimens and corticosteroids improves patient outcomes.
Area of Science:
- Neurology
- Infectious Diseases
Context:
- Subacute meningitis, primarily tuberculous meningitis (TbM) and fungal meningitis, presents a significant clinical challenge.
- Delayed treatment in these conditions is strongly linked to adverse patient outcomes, necessitating prompt intervention.
Purpose:
- To review recent clinical management strategies for subacute meningitis.
- To highlight updated therapeutic recommendations based on current clinical guidelines.
Summary:
- TbM management involves a 4-drug regimen for 2 months, followed by 2 drugs for at least 10 months, with adjunctive corticosteroids for non-HIV patients.
- Treatment for CNS Cryptococcosis and Candidiasis in non-HIV, non-transplant hosts includes induction therapy with lipid Amphotericin B and flucytosine, followed by fluconazole consolidation.
- Voriconazole is the recommended primary treatment for CNS Aspergillosis, including meningitis.
Impact:
- Early diagnosis and adherence to established guidelines can lead to successful management of these serious meningitides.
- Implementation of these updated therapeutic approaches aims to improve clinical outcomes for patients with subacute meningitis.
Related Concept Videos
Bacterial Meningitis I: Introduction
Bacterial Meningitis II: Pathophysiology
Viral Meningitis
Brain Abscess l: Introduction
Acute Pyelonephritis II: Diagnostic Studies and Management
Encephalitis l: Introduction

